JP2010501538A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010501538A5 JP2010501538A5 JP2009525110A JP2009525110A JP2010501538A5 JP 2010501538 A5 JP2010501538 A5 JP 2010501538A5 JP 2009525110 A JP2009525110 A JP 2009525110A JP 2009525110 A JP2009525110 A JP 2009525110A JP 2010501538 A5 JP2010501538 A5 JP 2010501538A5
- Authority
- JP
- Japan
- Prior art keywords
- particles
- dosage form
- solid dosage
- coating
- coated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 48
- 239000002245 particle Substances 0.000 claims 38
- 239000007909 solid dosage form Substances 0.000 claims 26
- 239000000546 pharmaceutical excipient Substances 0.000 claims 24
- 239000011248 coating agent Substances 0.000 claims 22
- 238000000576 coating method Methods 0.000 claims 22
- 229940122361 Bisphosphonate Drugs 0.000 claims 16
- 150000004663 bisphosphonates Chemical class 0.000 claims 16
- 239000007884 disintegrant Substances 0.000 claims 9
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 6
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 5
- 229920002678 cellulose Polymers 0.000 claims 5
- 239000001913 cellulose Substances 0.000 claims 5
- 235000010980 cellulose Nutrition 0.000 claims 5
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 5
- 239000008108 microcrystalline cellulose Substances 0.000 claims 5
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 5
- 239000000725 suspension Substances 0.000 claims 5
- 208000001132 Osteoporosis Diseases 0.000 claims 4
- 239000002552 dosage form Substances 0.000 claims 4
- 239000002002 slurry Substances 0.000 claims 4
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 claims 3
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 claims 3
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 claims 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 3
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 claims 3
- DKJJVAGXPKPDRL-UHFFFAOYSA-N Tiludronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)SC1=CC=C(Cl)C=C1 DKJJVAGXPKPDRL-UHFFFAOYSA-N 0.000 claims 3
- 238000010521 absorption reaction Methods 0.000 claims 3
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical group CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 claims 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 3
- 229940062527 alendronate Drugs 0.000 claims 3
- 229960002286 clodronic acid Drugs 0.000 claims 3
- ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 claims 3
- 229960005168 croscarmellose Drugs 0.000 claims 3
- 229960001681 croscarmellose sodium Drugs 0.000 claims 3
- 229960000913 crospovidone Drugs 0.000 claims 3
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 claims 3
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 3
- 229940009626 etidronate Drugs 0.000 claims 3
- 229940015872 ibandronate Drugs 0.000 claims 3
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 claims 3
- 229940046231 pamidronate Drugs 0.000 claims 3
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims 3
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims 3
- 229940089617 risedronate Drugs 0.000 claims 3
- 229920003109 sodium starch glycolate Polymers 0.000 claims 3
- 229940079832 sodium starch glycolate Drugs 0.000 claims 3
- 239000008109 sodium starch glycolate Substances 0.000 claims 3
- 229940019375 tiludronate Drugs 0.000 claims 3
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 claims 3
- 229960004276 zoledronic acid Drugs 0.000 claims 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 2
- 229920002472 Starch Polymers 0.000 claims 2
- 239000001506 calcium phosphate Substances 0.000 claims 2
- 229910000389 calcium phosphate Inorganic materials 0.000 claims 2
- 235000011010 calcium phosphates Nutrition 0.000 claims 2
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims 2
- 239000008101 lactose Substances 0.000 claims 2
- 239000008107 starch Substances 0.000 claims 2
- 229940032147 starch Drugs 0.000 claims 2
- 235000019698 starch Nutrition 0.000 claims 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical group OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 239000000845 maltitol Substances 0.000 claims 1
- 235000010449 maltitol Nutrition 0.000 claims 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims 1
- 229940035436 maltitol Drugs 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 229960001855 mannitol Drugs 0.000 claims 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 235000010356 sorbitol Nutrition 0.000 claims 1
- 229960002920 sorbitol Drugs 0.000 claims 1
- 238000005507 spraying Methods 0.000 claims 1
- 239000000811 xylitol Substances 0.000 claims 1
- 235000010447 xylitol Nutrition 0.000 claims 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims 1
- 229960002675 xylitol Drugs 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0616794.4A GB0616794D0 (en) | 2006-08-24 | 2006-08-24 | Solid dosage form |
| PCT/GB2007/003224 WO2008023184A2 (en) | 2006-08-24 | 2007-08-24 | Solid dosage form |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010501538A JP2010501538A (ja) | 2010-01-21 |
| JP2010501538A5 true JP2010501538A5 (OSRAM) | 2010-05-20 |
Family
ID=37102775
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009525110A Pending JP2010501538A (ja) | 2006-08-24 | 2007-08-24 | 固形剤型 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US8697124B2 (OSRAM) |
| EP (1) | EP2054038A2 (OSRAM) |
| JP (1) | JP2010501538A (OSRAM) |
| AU (1) | AU2007287365B2 (OSRAM) |
| BR (1) | BRPI0714360A2 (OSRAM) |
| CA (1) | CA2661547A1 (OSRAM) |
| GB (1) | GB0616794D0 (OSRAM) |
| NZ (1) | NZ574798A (OSRAM) |
| WO (1) | WO2008023184A2 (OSRAM) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101230178B1 (ko) * | 2010-06-10 | 2013-02-06 | 주식회사 네비팜 | 골다공증 예방 또는 치료용 조성물 및 이의 제조방법 |
| SG188509A1 (en) * | 2010-09-13 | 2013-04-30 | Bev Rx Inc | Aqueous drug delivery system comprising off - flavor masking agent |
| FI126168B (en) | 2012-09-18 | 2016-07-29 | Novaldmedical Ltd Oy | A method for coating pharmaceutical substrates |
| EP3419659A1 (en) | 2016-02-23 | 2019-01-02 | The Regents of the University of Colorado, A Body Corporate | Compositions and methods for making and using thermostable immunogenic formulations with increased compatibility of use as vaccines against one or more pathogens |
| CN106631735B (zh) * | 2016-12-03 | 2023-10-20 | 湖北泰盛化工有限公司 | 一种多聚甲醛再解聚的系统及其方法和应用 |
| KR102496427B1 (ko) | 2018-01-16 | 2023-02-06 | 어플라이드 머티어리얼스, 인코포레이티드 | 금속 산화물로 캡슐화된 약물 조성물들 및 그의 제조 방법들 |
| WO2021041673A1 (en) | 2019-08-27 | 2021-03-04 | Applied Materials, Inc. | Vapor phase coating technology for pharmaceutical abuse deterrent formulations |
| GB202001237D0 (en) * | 2020-01-29 | 2020-03-11 | Sisteks D O O | Granular pharmaceutical product for oral administration from a pre-filled straw and method of manufacturing such pharmaceutical product |
| TWI870622B (zh) | 2020-10-02 | 2025-01-21 | 美商應用材料股份有限公司 | 製備氧化矽塗佈藥品的低溫處理 |
| WO2023056304A1 (en) | 2021-09-30 | 2023-04-06 | Applied Materials, Inc. | Low temperature silicon oxide coating for pharmaceutical applications |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2122479C (en) | 1991-11-22 | 1998-08-25 | Richard John Dansereau | Risedronate delayed-release compositions |
| US5358941A (en) | 1992-12-02 | 1994-10-25 | Merck & Co., Inc. | Dry mix formulation for bisphosphonic acids with lactose |
| US5431920A (en) | 1993-09-21 | 1995-07-11 | Merck Frosst, Canada, Inc. | Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents |
| FI94926C (fi) * | 1993-11-12 | 1995-11-27 | Leiras Oy | Menetelmä klodronaattivalmisteen valmistamiseksi |
| TW390813B (en) | 1994-04-29 | 2000-05-21 | Merck & Co Inc | Wet granulation formulation for bisphosphonic acids |
| US20010007863A1 (en) * | 1998-06-18 | 2001-07-12 | Merck & Co., Inc. | Wet granulation formulation for bisphosphonic acids |
| DE19615812A1 (de) * | 1996-04-20 | 1997-10-23 | Boehringer Mannheim Gmbh | Pharmazeutische Zubereitung enthaltend Diphosphonsäuren zur oralen Applikation |
| RU2193880C2 (ru) * | 1997-06-11 | 2002-12-10 | Дзе Проктер Энд Гэмбл Компани | Покрытая пленкой таблетка улучшенной безопасности для верхних отделов желудочно-кишечного тракта |
| SE9703691D0 (sv) | 1997-10-10 | 1997-10-10 | Astra Ab | Pharmaceutical compositions |
| US7008645B2 (en) | 1998-07-14 | 2006-03-07 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Method of inhibiting restenosis using bisphosphonates |
| US6984400B2 (en) | 1998-07-14 | 2006-01-10 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Method of treating restenosis using bisphosphonate nanoparticles |
| FR2781793B1 (fr) * | 1998-08-03 | 2001-07-20 | Prographarm Lab | Procede de fabrication de granules de gabapentine enrobes |
| EP0998933A1 (de) * | 1998-10-09 | 2000-05-10 | Boehringer Mannheim Gmbh | Verfahren zur Herstellung von bisphosphonathaltigen pharmazeutischen Zusammensetzungen zur oralen Applikation |
| EP0998932A1 (de) | 1998-10-09 | 2000-05-10 | Boehringer Mannheim Gmbh | Feste pharmazeutische Darreichungsform enthaltend Diphosphonsäure oder deren Salze und Verfahren zu ihrer Herstellung |
| US6740341B1 (en) * | 1998-11-25 | 2004-05-25 | Cima Labs Inc. | Taste masking rapid release coating system |
| SE9901272D0 (sv) | 1999-04-09 | 1999-04-09 | Astra Ab | New improved formulation |
| AR024462A1 (es) | 1999-07-01 | 2002-10-02 | Merck & Co Inc | Tabletas farmaceuticas |
| AR021347A1 (es) | 1999-10-20 | 2002-07-17 | Cipla Ltd | Una composicion farmaceutica que contiene acido(s) bisfosfoncio o sal(es) del mismo y un proceso de preparacion de la misma |
| AU2127200A (en) | 1999-11-02 | 2001-05-14 | Cipla Limited | A pharmaceutical composition containing bisphosphonic acid(s) or salt(s) thereofand a process of preparing thereof |
| US6468559B1 (en) | 2000-04-28 | 2002-10-22 | Lipocine, Inc. | Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods |
| PL196485B1 (pl) | 2000-05-11 | 2008-01-31 | Inst Farmaceutyczny | Stała doustna kompozycja farmaceutyczna zawierająca aminową pochodną kwasu bisfosfonowego i sposób jej wytwarzania |
| US6350471B1 (en) * | 2000-05-31 | 2002-02-26 | Pharma Pass Llc | Tablet comprising a delayed release coating |
| SE0102887D0 (sv) * | 2001-08-29 | 2001-08-29 | Astrazeneca Ab | New formulation |
| US7488496B2 (en) * | 2002-03-06 | 2009-02-10 | Christer Rosen | Effervescent compositions comprising bisphosphonates and methods related thereto |
| EP1490031A1 (en) * | 2002-03-07 | 2004-12-29 | Vectura Limited | Fast melt multiparticulate formulations for oral delivery |
| US20040138180A1 (en) | 2002-10-03 | 2004-07-15 | Barr Laboratories, Inc. | Bisphosphonate composition and process for the preparation thereof |
| US6781011B2 (en) * | 2002-12-13 | 2004-08-24 | Texas Christian University | Bis-H-phosphinic acid derivatives as precursors to therapeutic bisphosphonates and uses thereof |
| EP1596870B2 (en) | 2002-12-20 | 2011-04-06 | F. Hoffmann-La Roche AG | High dose ibandronate formulation |
| CA2520321A1 (en) * | 2003-04-04 | 2004-10-14 | Pharmacia Corporation | Oral extended release compressed tablets of multiparticulates |
| CA2559670A1 (en) * | 2003-04-14 | 2004-10-28 | Gabor Pragai | Stable amlodipine maleate formulations |
| GR1004660B (el) | 2003-06-25 | 2004-08-25 | ������������, �������� ��� ����������� �������� �������� ��� �.�. ��������-������������ �.�. | Βελτιωμενες φαρμακευτικες συνθεσεις του τριυδρικου αλενδρονικου νατριου και μεθοδοι παρασκευης τους |
| EP1680092A2 (en) * | 2003-09-29 | 2006-07-19 | Cipla Ltd. | Pharmaceutical formulation with improved stability |
| GB0330255D0 (en) | 2003-12-31 | 2004-02-04 | Vectura Ltd | Multiparticulate formulations for oral delivery |
| CA2555406A1 (en) | 2004-02-19 | 2005-09-01 | Teva Pharmaceutical Industries, Ltd. | Improved therapy using a combination of raloxifene and alendronate |
| US7645459B2 (en) | 2004-05-24 | 2010-01-12 | The Procter & Gamble Company | Dosage forms of bisphosphonates |
| EP1781258A1 (en) | 2004-08-20 | 2007-05-09 | Mepha AG | Formulations of bisphosphonates |
| WO2006046100A1 (en) | 2004-10-25 | 2006-05-04 | Ranbaxy Laboratories Limited | Pharmaceutical composition of alendronic acid |
| AU2005309601A1 (en) * | 2004-11-23 | 2006-06-01 | Neuromolecular Pharmaceuticals, Inc. | Composition comprising a sustained release coating or matrix and an NMDA receptor antagonist, method for administration such NMDA antagonist to a subject |
| WO2006100527A1 (en) * | 2005-03-24 | 2006-09-28 | Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. | Effervescent tablet containing sodium alendronate and related use and process |
-
2006
- 2006-08-24 GB GBGB0616794.4A patent/GB0616794D0/en not_active Ceased
-
2007
- 2007-08-24 CA CA002661547A patent/CA2661547A1/en not_active Abandoned
- 2007-08-24 JP JP2009525110A patent/JP2010501538A/ja active Pending
- 2007-08-24 EP EP07789312A patent/EP2054038A2/en not_active Withdrawn
- 2007-08-24 US US12/310,388 patent/US8697124B2/en active Active
- 2007-08-24 BR BRPI0714360-5A patent/BRPI0714360A2/pt not_active IP Right Cessation
- 2007-08-24 NZ NZ574798A patent/NZ574798A/en not_active IP Right Cessation
- 2007-08-24 WO PCT/GB2007/003224 patent/WO2008023184A2/en not_active Ceased
- 2007-08-24 AU AU2007287365A patent/AU2007287365B2/en not_active Ceased
-
2014
- 2014-04-14 US US14/251,805 patent/US20140220128A1/en not_active Abandoned
-
2015
- 2015-10-09 US US14/880,019 patent/US10420725B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010501538A5 (OSRAM) | ||
| JP3725427B2 (ja) | ビホスホネートを含む経口医薬品組成物の製造方法 | |
| JP6150777B2 (ja) | 固体薬学的組成物およびそれらの生産のためのプロセス | |
| US10420725B2 (en) | Solid dosage form of coated bisphosphonate particles | |
| CA2484494C (en) | High dose ibandronate formulation | |
| PL194552B1 (pl) | Środek farmaceutyczny w stałej jednostkowej postaci dawkowanej zawierający kwas difosfonowy lub jego fizjologicznie zgodną sól i sposób jego wytwarzania | |
| KR20060100395A (ko) | 안정성이 개선된 약제학적 제제 | |
| JP2010513328A5 (OSRAM) | ||
| AU2007101090A4 (en) | Process for the preparation of a solid pharmaceutical dosage form | |
| MX2007014056A (es) | Composicion farmaceutica solida para administracion oral de acido ibandronico o una sal o un hidrato farmaceuticamente aceptable del mismo, procedimiento de preparacion de dicha composicion mediante compresion directa, formulaciones farmaceuticas que | |
| AU2006222690A1 (en) | High dose ibandronate formulation | |
| MXPA01003407A (en) | Process for the preparation of oral pharmaceutical compositions comprising biphosphonates |